Breaking News

Samsung BioLogics Signs CMO Contract

Deal valued at $105 million

Related CONTENT

02.06.18

Samsung BioLogics has signed a CMO contract with an Asian pharmaceutical company. This contract is in addition to an already existing manufacturing contract. The approximate value of the contract will be $105 million for one year in 2018. The company said other terms of the agreement related to company's name, product, and production factory will not be disclosed.

Related Searches

Suggested For You

Samsung Biologics to Participate in Frontier 1.5D Initiative

Samsung Biologics to Participate in Frontier 1.5D Initiative

Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond

Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond

Bioprocessing Technologies: Stainless Steel vs Single Use

Bioprocessing Technologies: Stainless Steel vs Single Use

Samsung Biologics Signs Agreement with Kahr Medical

Samsung Biologics Signs Agreement with Kahr Medical

Samsung Biologics Expands Vaccine Manufacturing Capabilities

Samsung Biologics Expands Vaccine Manufacturing Capabilities

Samsung Biologics, TG Therapeutics Expand Manufacturing Collaboration

Samsung Biologics, TG Therapeutics Expand Manufacturing Collaboration

Samsung Bioepis Opens New Headquarters

Samsung Bioepis Opens New Headquarters

Samsung Biologics Continues to Leverage Digitalization to Optimize Client Experience

Samsung Biologics Continues to Leverage Digitalization to Optimize Client Experience

Samsung Biologics Names John Rim as President and CEO

Samsung Biologics Names John Rim as President and CEO

Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

Samsung Biologics Launches Virtual Showroom

Samsung Biologics Launches Virtual Showroom

Samsung Biologics Breaks Ground on

Samsung Biologics Breaks Ground on 'Super Plant'

Samsung Biologics

Samsung Biologics

Samsung Biologics Partners with Eli Lilly

Samsung Biologics Partners with Eli Lilly

Related Breaking News

Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News

FUJIFILM Diosynth Biotechnologies Invests £400M in UK Bio-Mfg. Site

Expansion will more than double the site’s development and manufacturing footprint and is expected to create as many as 350 highly-skilled jobs in Teesside.
12.02.21
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News

CordenPharma Expands Specialty Lipids Production in Chenôve

Invests in Supercritical Fluid Chromatography technology for compound separation, an efficient and cost-effective process for purifying lipids.
12.02.21
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

Emergex T-Cell Priming COVID Vax Candidate Holds Potential Against Omicron

Phase I vaccine candidate has the potential to be effective against all currently known variants and would eliminate the need for seasonal booster.
11.30.21
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News

Valneva, IDT Biologika Enter COVID Vax Mfg. Pact

IDT Biologika will produce VLA2001’s drug substance at its Biosafety Level 3 facilities in Dessau-Roßlau, Germany.
11.29.21
Biologics, Proteins, Vaccines | Breaking News

Nykode Therapeutics Selects BioConnection to Manufacture Lead Vax Candidate

BioConnection has more than fifteen years of experience and serves a global customer base.
11.29.21
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances

GreenLight Biosciences, Samsung Biologics Partner to Advance New RNA Covid Vax

Aims to accelerate the production of GreenLight’s vaccine candidate for Phase III clinical trials and commercial scale.
11.29.21
Bioanalytical Services | Biologics, Proteins, Vaccines | Breaking News | Industry News | Laboratory Testing | Microbiology

Lonza Expands Microbial Development Labs

New development capacity will consolidate the microbial footprint at the Visp site and add new high throughput equipment and automation processes.
11.23.21
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Trials & Filings

BioNTech's FixVac Gets Fast Track in Advanced Melanoma

FixVac platform uses a fixed combination of mRNA-encoded, tumor-associated antigens to trigger a precise immune response against cancer.
11.19.21
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

Gilead Ops in For Three Programs in Arcus Biosciences Portfolio

Aims to accelerate clinical development in oncology and facilitate the exploration of treatment combinations across portfolios.
11.18.21
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

Novo Nordisk to Acquire Dicerna Pharmaceuticals for $3.3B

Gains Dicerna’s ribonucleic acid interference (RNAi) platform to develop therapies to selectively silence genes that cause or contribute to disease.
11.18.21
Bioanalytical Services | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News | Laboratory Testing

BioMagnetic Solutions to Build cGMP Production Facility at Penn State

Site is expected to be fully operational in mid-2022 with more than 13,000 sq.-ft. of purpose-built office, lab, and cGMP manufacturing space.
11.18.21
Biologics, Proteins, Vaccines | Breaking News | Industry News | Trials & Filings

EMA Begins Evaluation of Novavax' COVID-19 Vaccine

Nuvaxovid assessment will proceed under an accelerated timeline, with an opinion issued potentially within weeks.
11.17.21
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

SOTIO, LegoChem Biosciences Enter ADC License Agreement

SOTIO licenses LegoChem Biosciences technology for five new antibody-drug conjugate programs targeting distinct tumor-associated antigens.
11.16.21
Analytical Services | Bio News | Bioanalytical Services | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News | Laboratory Testing

WuXi ATU Opens New Cell and Gene Therapy Testing Facility

Triples testing capacity with 140,000 square feet of new laboratory space.
11.12.21
Biologics, Proteins, Vaccines | Breaking News | Industry News

Thermo Fisher Launches Gibco AAV Production System

The all-in-one AAV-MAX system is an optimized solution that aims to simplify the AAV vector production workflow.
11.11.21